The Investigators will assess the mean intraocular pressure change from baseline, the change in the number of medications from baseline, the proportion of patients needing additional incisional surgery, and the incidence of adverse events. The Investigators hypothesize that patients receiving the combined standalone iStent infinite and iDose will experience a safe and significant reduction in mean intraocular pressure and number of medications during the study time period.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Moderate to severe open angle glaucoma (including POAG, PG, and PXG)
Open angle configuration (Shaffer grade ≥ 3), normal angle anatomy9
Visual acuity HM or better
VF MD -6dB or worse
Failed medical therapy and/or laser treatment
Incisional glaucoma surgery contemplated as next intervention
Phakic or pseudophakic
You may not be if
Traumatic, uveitic, neovascular glaucoma, or angle closure glaucoma
Previous incisional glaucoma surgery
ALT; History of iridotomy, SLT, or micropulse laser trabeculoplasty within the prior 90 days
Active ocular inflammation or edema, clinically significant corneal dystrophy
Corneal or other pathology preventing accurate Goldmann applanation tonometry